“Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study”, J of Skin, vol. 7, no. 6, p. s258, Nov. 2023, doi: 10.25251/skin.7.supp.258.